Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 July 2021, including: Johnson & Johnson’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis AG; Biogen, Inc.’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19..
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J&J's COVID-19 Vaccine On Track To Generate $2.5bn This Year" - Scrip, 21 Jul, 2021.)
(Also see "Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing" - Scrip, 21 Jul, 2021.)
(Also see "Biogen: Aduhelm Price Is Part Of Alzheimer's ‘Evolution’" - Scrip, 20 Jul, 2021.)
(Also see "GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back" - Scrip, 16 Jul, 2021.)
(Also see "Global Herd Immunity Against COVID-19 Unlikely, Says Ebola Vaccine Developer" - Scrip, 20 Jul, 2021.)